Drug intelligence / Profile preview

Compound Tufuling

Development stage: Unknown
Administration: Oral

Overview

Compound Tufuling is a traditional Chinese medicine formulation primarily used to treat conditions like hyperuricemia and arthritis. It is derived from *Smilax glabra* (Tu Fu Ling) and other ingredients, though specific components may vary. The formulation is known for its anti-inflammatory and hypouricemic effects, helping to reduce serum uric acid levels and alleviate symptoms associated with gout and arthritis.

Other names: Compound Tufuling Granules (CTG)Compound Tufuling Oral Liquid (CoTOL)

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)XO (Xanthine Oxidoreductase)ALDH2 (Mitochondrial Aldehyde Dehydrogenase)URAT1 (Uric Acid Transporter 1)CASP3 (Caspase-3)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on Compound Tufuling.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compound Tufuling.

Explore the full profile